Patent ID: 7872052

Claim:
A method for treatment of a skin disease in a mammal, wherein the skin disease is selected from the group consisting of atopic dermatitis, contact dermatitis, eczema, psoriasis, acne, epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus, and wherein the mammal has symptoms of the skin disease and the treatment reduces the symptoms wherein the method comprises topically administering to the mammal an effective amount of at least one compound with formula I or II: wherein X is O or S; Y is independently O, S, NH or N if the nitrogen atom is bonded to an adjacent carbon atom via a double bond; Z is independently O, NH or N if the nitrogen atom is bonded to an adjacent carbon atom via a double bond; W, Q, V, and T are independently CH, CH 2 , S, N, or O; ring A, ring B, ring C and ring D may be aromatic, saturated or partly saturated; R 1 and R 2 are optional substitutents independently selected from C 1-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl or C 3-6 -cycloalkyl, each optionally substituted with halogen, OH, NH 2 , NHR 4 , N(R 4 ) 2 , NHCOR 4 , C 1-6 -alkoxy, trifluoromethoxy, carbamoyl, CONHR 4 or CON(R 4 ) 2 , H, halogen, CF 3 , C 1-6 -alkoxy, C 1-6 alkylthio, OCF 3 , COOH, CN, CONH 2 , CONHR 4 , OH, NO 2 , NH 2 , NHR 4 , N(R 4 ) 2 , NHCOR 4 , NHSO 2 R 4 , CON(R 4 ) 2 , CONHSO 2 R 4 , SO 2 NH 2 , SO 2 NHR 4 , SO 2 R 4 , SOR 4 , C 1-4 alkoxycarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, alkylphenyl, or tetrazole; or R 1 and R 2 , when bonded to adjacent atoms in ring A or ring C, optionally together form a moiety —(CH 2 ) n —, where n=1-5, and wherein 1, 2 or 3 CH 2 units in said moiety are optionally replaced by 1, 2 or 3 heteroatoms, wherein each heteroatom is individually selected from the group consisting of O, S, NH and N if the nitrogen atom is bonded to an adjacent atom via a double bond, and wherein said moiety may optionally be substituted with 1, 2 or 3 substitutents individually selected from the group consisting of halogen, OH, NH 2 , NHR 4 , N(R 4 ) 2 , NHCOR 4 , C 1-6 alkoxy, trifluoromethoxy, carbamoyl, CONHR 4 , or CON(R 4 ) 2 ; R 3 is aryl or heteroaryl, each optionally substituted with one or more halogen, CF 3 , C 1-6 -alkoxy, C 1-6 -alkylthio, OCF 3 , COOH, CN, CONH 2 , CONHR 4 , OH, NO 2 , NH 2 , NHR 4 , N(R 4 ) 2 , NHCOR 4 , NHSO 2 R 4 , CON(R 4 ) 2 , CONHSO 2 R 4 , SO 2 NH 2 , SO 2 NHR 4 , SO 2 R 4 , SOR 4 , C 1-4 -alkoxycarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, alkylphenyl, tetrazole, C 1-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl or C 3-6 -cycloalkyl, each C 1-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl or C 3-6 -cycloalkyl being optionally substituted with halogen, CF 3 , OCF 3 , COOH, CN, CONH 2 , CONHR 4 , CON(R 4 ) 2 , OH, NO 2 , NH 2 , NHR 4 , N(R 4 ) 2 , NHCOR 4 , NHSO 2 R 4 , SO 2 NH 2 , SO 2 NHR 4 , SO 2 R 4 , SOR 4 , C 1-4 alkoxy, or carbamoyl; and R 4 is C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 3-6 -cycloalkyl, C 1-6 -alkylthio, aryl, aryloxy, heteroaryl, or heteroaryloxy; or a pharmaceutical acceptable salt thereof.